Table 3. Cost-effectiveness analysis of meglumine antimoniate intralesional infiltration compared to endovenous meglumine antimoniate for cutaneous leishmaniasis treatment in Brazil.

Strategy	Cost	Incremental cost	Effectiveness	Incremental effectiveness	ICER	Dominance
EV-MA	494.16		0,684			dominated
IL-MA	330.81	-163.34	0.870	0.186	-864.37	undominated

ICER. Incremental cost effectiveness EV-MA: meglumine antimoniate administered endovenously

IL-MA: meglumine antimoniate intralesional infiltration